Roy Proujansky insider trades: Innovate Biopharmaceuticals (INNT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Roy reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 24, 2019 | INNT | ↑ Buy | 1,000 | $1.28 | $1K | Direct | May 28, 2019 (4d) |
| Nov 30, 2018 | INNT | ↑ Buy | 1,400 | $2.63 | $4K | Direct | Dec 3, 2018 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Roy Proujansky's insider trades
Roy Proujansky is a director at Innovate Biopharmaceuticals (INNT). Since Nov 30, 2018, Roy has reported 2 open-market purchases worth $5K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INNT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.